Status:
COMPLETED
The Pharmacokinetics and Pharmacodynamics of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria
Lead Sponsor:
Radboud University Medical Center
Conditions:
Paroxysmal Nocturnal Hemoglobinuria
Eculizumab
Eligibility:
All Genders
18+ years
Brief Summary
Because of the inter and intra individual variability in pharmacokinetics and pharmacodynamics of eculizumab in PNH patients, a tailored treatment approach for the individual is probably preferable. T...
Detailed Description
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder which is characterized by hemolytic anemia, cytopenias and thrombosis. PNH is caused by clonal expansion of hematopoietic ste...
Eligibility Criteria
Inclusion
- Diagnosis of PNH
- Treated with eculizumab
- Willing to give informed consent
Exclusion
- Not applicable
Key Trial Info
Start Date :
February 23 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2022
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT04079257
Start Date
February 23 2021
End Date
July 1 2022
Last Update
August 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboudumc
Nijmegen, Netherlands